Stuelpnagel John R's Form 4 filing
10x Genomics, Inc. (TXG) · filed Aug 13, 2026
- Accession no.
- 0001610717-26-000358
- Filed
- Aug 13, 2026, 4:11 PM ET
- Trade date
- Aug 11, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.16M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stuelpnagel John RCIK 0001189140 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Class A Common Stock | SSaleDisposed | −17,000 | $57.58F1 | −$978,880.4 | 351,436 | Direct | |
| Aug 11, 2026 | Class A Common Stock | SSaleDisposed | −3,000 | $58.73 | −$176,175 | 348,436 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.